ELDN PE Ratio & Valuation,Is ELDN Overvalued

ELDN Relative Valuation

ELDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ELDN is overvalued; if below, it's undervalued.

Historical Valuation

Eledon Pharmaceuticals Inc (ELDN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.17. The fair price of Eledon Pharmaceuticals Inc (ELDN) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：1.71

Fair

-1.71

0.00

EV/EBITDA

Eledon Pharmaceuticals Inc. (ELDN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.48. The thresholds are as follows: Strongly Undervalued below -16.67, Undervalued between -16.67 and -9.08, Fairly Valued between 6.11 and -9.08, Overvalued between 6.11 and 13.71, and Strongly Overvalued above 13.71. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.37

EV/EBIT

Eledon Pharmaceuticals Inc. (ELDN) has a current EV/EBIT of -0.37. The 5-year average EV/EBIT is -0.45. The thresholds are as follows: Strongly Undervalued below -4.08, Undervalued between -4.08 and -2.27, Fairly Valued between 1.36 and -2.27, Overvalued between 1.36 and 3.18, and Strongly Overvalued above 3.18. The current Forward EV/EBIT of -0.37 falls within the Historic Trend Line -Fairly Valued range.

0.00

Eledon Pharmaceuticals Inc. (ELDN) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-2.01

P/OCF

Eledon Pharmaceuticals Inc. (ELDN) has a current P/OCF of -2.01. The 5-year average P/OCF is -1.58. The thresholds are as follows: Strongly Undervalued below -5.12, Undervalued between -5.12 and -3.35, Fairly Valued between 0.19 and -3.35, Overvalued between 0.19 and 1.96, and Strongly Overvalued above 1.96. The current Forward P/OCF of -2.01 falls within the Historic Trend Line -Fairly Valued range.

-1.62

P/FCF

Eledon Pharmaceuticals Inc. (ELDN) has a current P/FCF of -1.62. The 5-year average P/FCF is -1.39. The thresholds are as follows: Strongly Undervalued below -4.84, Undervalued between -4.84 and -3.11, Fairly Valued between 0.34 and -3.11, Overvalued between 0.34 and 2.06, and Strongly Overvalued above 2.06. The current Forward P/FCF of -1.62 falls within the Historic Trend Line -Fairly Valued range.

Eledon Pharmaceuticals Inc (ELDN) has a current Price-to-Book (P/B) ratio of 1.08. Compared to its 3-year average P/B ratio of -0.53 , the current P/B ratio is approximately -305.05% higher. Relative to its 5-year average P/B ratio of -0.10, the current P/B ratio is about -1153.99% higher. Eledon Pharmaceuticals Inc (ELDN) has a Forward Free Cash Flow (FCF) yield of approximately -54.56%. Compared to its 3-year average FCF yield of -60.94%, the current FCF yield is approximately -10.47% lower. Relative to its 5-year average FCF yield of -54.24% , the current FCF yield is about 0.58% lower.

1.08

P/B

Median3y

-0.53

Median5y

-0.10

-54.56

FCF Yield

Median3y

-60.94

Median5y

-54.24

Competitors Valuation Multiple

The average P/S ratio for ELDN's competitors is 103.32, providing a benchmark for relative valuation. Eledon Pharmaceuticals Inc Corp (ELDN) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ELDN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ELDN in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Eledon Pharmaceuticals Inc (ELDN) currently overvalued or undervalued?

What is Eledon Pharmaceuticals Inc (ELDN) fair value?

ELDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Eledon Pharmaceuticals Inc (ELDN) is between to according to relative valuation methord.

How does ELDN's valuation metrics compare to the industry average?

The average P/S ratio for ELDN's competitors is 103.32, providing a benchmark for relative valuation. Eledon Pharmaceuticals Inc Corp (ELDN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Eledon Pharmaceuticals Inc (ELDN) as of Dec 15 2025?

As of Dec 15 2025, Eledon Pharmaceuticals Inc (ELDN) has a P/B ratio of 1.08. This indicates that the market values ELDN at 1.08 times its book value.

What is the current FCF Yield for Eledon Pharmaceuticals Inc (ELDN) as of Dec 15 2025?

As of Dec 15 2025, Eledon Pharmaceuticals Inc (ELDN) has a FCF Yield of -54.56%. This means that for every dollar of Eledon Pharmaceuticals Inc’s market capitalization, the company generates -54.56 cents in free cash flow.

What is the current Forward P/E ratio for Eledon Pharmaceuticals Inc (ELDN) as of Dec 15 2025?

As of Dec 15 2025, Eledon Pharmaceuticals Inc (ELDN) has a Forward P/E ratio of -1.71. This means the market is willing to pay $-1.71 for every dollar of Eledon Pharmaceuticals Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Eledon Pharmaceuticals Inc (ELDN) as of Dec 15 2025?

As of Dec 15 2025, Eledon Pharmaceuticals Inc (ELDN) has a Forward P/S ratio of 0.00. This means the market is valuing ELDN at $0.00 for every dollar of expected revenue over the next 12 months.

ELDN Valuation